Triple-negative breast cancer (TNBC) doesn’t have a single cause. It arises from a combination of genetic mutations, hormonal and reproductive factors, and biological processes that researchers are still working to fully map. What sets TNBC apart is what the tumor cells lack: they test negative for estrogen receptors, progesterone receptors, and excess HER2 protein. That means the cancer can’t be treated with hormone therapies or HER2-targeted drugs, which is why understanding its causes matters so much for prevention and treatment.
TNBC accounts for roughly 15 to 30 percent of all invasive breast cancer diagnoses in the United States, and it tends to behave more aggressively than other subtypes. Here’s what drives it.
Genetic Mutations Play a Major Role
The strongest known risk factor for TNBC is an inherited mutation in the BRCA1 gene. About 10 to 15 percent of triple-negative breast cancers in white women are linked to BRCA1 mutations. In African American women, that number jumps to roughly 35 percent. BRCA1 normally helps repair damaged DNA in cells. When the gene is mutated and can’t do its job, cells accumulate errors that can eventually become cancerous, and those cancers disproportionately take the triple-negative form.
BRCA1 isn’t the only gene involved. A large study identified five genes with mutations strongly linked to increased TNBC risk: BARD1, BRCA1, BRCA2, PALB2, and RAD51D. Three additional genes, BRIP1, RAD51C, and RAD51D, were found to moderately raise TNBC risk. These had previously been associated only with ovarian cancer, which expanded the picture of who carries genetic susceptibility. All of these genes are involved in DNA repair, and when any of them malfunction, cells lose a critical safety mechanism against tumor development.
Race, Age, and Hormonal Timing
TNBC does not affect all populations equally. African American women develop triple-negative breast cancer at significantly higher rates than white women, and the disparity is especially stark before menopause. The Carolina Breast Cancer Study found that 39 percent of invasive breast cancers in premenopausal African American women were the basal-like subtype of TNBC. That’s compared to 14 percent in postmenopausal African American women and 16 percent in white women of any menopausal status.
This pattern suggests that hormonal environment matters. Premenopausal women have higher circulating levels of estrogen and progesterone, yet TNBC cells don’t respond to those hormones. The connection likely has more to do with how breast tissue remodels during reproductive years and how that remodeling interacts with genetic susceptibility. The racial disparity also points to a combination of biological factors, including differences in the frequency of BRCA1 mutations, and structural factors like unequal access to screening and care.
Pregnancy and Breastfeeding Shift Risk
Reproductive history has a unique and somewhat counterintuitive relationship with TNBC. For most types of breast cancer, having children is generally protective. For TNBC, it’s more complicated: having multiple pregnancies without breastfeeding actually increases risk. Parous women who never breastfed had a 68 percent higher risk of TNBC compared to those who did breastfeed. That elevated risk was essentially erased by breastfeeding.
The duration of breastfeeding matters substantially. Women who breastfed for more than 12 months reduced their TNBC risk by up to 42 percent compared to mothers who didn’t breastfeed at all. Shorter durations of under six months were associated with a 1.4 to 2.0 times higher risk, depending on the number of pregnancies and race. African American women who breastfed for six months or more showed up to an 82 percent lower risk of TNBC.
The likely mechanism involves what happens to breast tissue after pregnancy. When a woman stops breastfeeding abruptly or doesn’t breastfeed, the milk-producing tissue undergoes a rapid breakdown process called involution. This triggers inflammation in the breast, which can create a microenvironment that favors aggressive cancer development. Longer breastfeeding allows for a more gradual transition and appears to reshape breast tissue in a way that’s protective.
Body Fat Distribution and Metabolic Health
The connection between body weight and TNBC is more nuanced than a simple “obesity raises risk” statement. Research from the Carolina Breast Study found that a high waist-to-hip ratio, which reflects where fat is stored rather than total body weight, was significantly linked to increased TNBC risk in both premenopausal and postmenopausal African American women. Interestingly, overall BMI of 30 or higher did not show a significant association with TNBC on its own.
This distinction matters because abdominal fat is more metabolically active than fat stored in other areas. It produces higher levels of inflammatory signals and alters how the body processes insulin. Over the past decade, researchers have connected obesity and the local environment around breast tumors to signaling pathways that promote aggressive cancer biology. Chronic inflammation and elevated insulin signaling can push breast cells toward the kind of unchecked growth that characterizes TNBC, particularly when other risk factors like genetic susceptibility or reproductive history are also present.
Where TNBC Starts in the Breast
Not all breast cells are equally likely to become cancerous, and the cell type that gives rise to a tumor helps determine what kind of cancer develops. Research published in the Proceedings of the National Academy of Sciences found that the majority of human breast cancers, including both hormone-receptor-positive and triple-negative types, likely originate from a specific group of cells called luminal epithelial cells. These are the cells that line the milk ducts.
This was a surprising finding because TNBC often has features that resemble basal cells, which sit in a different layer of breast tissue. Scientists initially assumed basal-like cancers came from basal cells. Instead, the evidence suggests that luminal cells can transform into cancers with basal characteristics, meaning the cancer’s appearance under a microscope doesn’t necessarily reveal its cell of origin. A smaller subset of rare, aggressive breast tumors called metaplastic cancers do appear to arise from basal cells, but these are uncommon.
Why TNBC Is Harder to Treat
The same features that define TNBC also explain its treatment challenges. Hormone-receptor-positive cancers can be starved by blocking estrogen. HER2-positive cancers can be targeted with drugs that bind to the excess HER2 protein. TNBC has neither of those vulnerabilities, which leaves chemotherapy as the primary systemic treatment, though newer options like immunotherapy and drugs targeting DNA repair defects in BRCA-mutated tumors have expanded the toolkit.
TNBC also tends to recur within a narrower window. If it comes back, it’s usually within the first five years after treatment. After that window, the recurrence risk drops substantially, which is the opposite pattern of hormone-receptor-positive cancers, where the risk of recurrence can persist for 10 to 20 years. This early recurrence pattern reflects the biology of the tumor: TNBC cells divide quickly, so if any survive treatment, they tend to regrow relatively fast rather than lying dormant.
Multiple Factors Working Together
No single cause explains most cases of TNBC. A woman might carry a BRCA1 mutation that makes her breast cells vulnerable to DNA damage, have children in her twenties without breastfeeding, and carry excess abdominal fat that creates a pro-inflammatory environment in breast tissue. Each factor nudges risk upward, and their combination can be more powerful than any one alone.
The racial disparity in TNBC illustrates this layered causation. African American women have higher rates of BRCA1 mutations, historically lower rates of breastfeeding, and higher prevalence of central obesity. These biological and social factors converge to produce a disease burden that is disproportionate and deeply intertwined with both genetics and lived experience. Understanding the causes of TNBC means recognizing that it sits at the intersection of inherited biology, reproductive choices, metabolic health, and the inequities that shape who is most exposed to each of these risks.